Global clinical cancer genomics company Inivata has announced a strategic partnership with Carolinas HealthCare System's Levine Cancer Institute and the subsequent formation of the Inivata Knowledge Accumulation Network (IKAN).
Levine Cancer Institute will be the founding member of IKAN, which will be a global network of world-leading cancer centres working in partnership with Inivata to assess the potential of liquid biopsy to transform cancer care and improve patient outcomes.
“Inivata's InVision liquid biopsy platform is innovative, highly sensitive and has great potential in clinical practice,” commented Edward Kim, Solid Tumor Oncology and Investigational Therapeutics and Donald S. Kim distinguished chair for cancer research, Levine Cancer Institute. “I am delighted to be working with the first-class team at Inivata in the official formation of IKAN. The network will serve to facilitate our common goal of improving treatment decisions and outcomes for patients. We already have a number of projects underway, including a recent grant from the V Foundation, to explore the various applications of ctDNA in revolutionising patient management.”
“We are excited to be partnering with the world-leading Levine Cancer Institute to form the Inivata Knowledge Accumulation Network,” said Clive Morris, CMO of Inivata. “The sharing of knowledge between world-leaders is crucial for continued advancement of the field, and we anticipate IKAN will provide an efficient platform for innovative conversations and collaborations. The opportunity to continue our work with leading cancer centres on a range of clinical projects across different cancer types will enable the swift development and validation of our InVision platform.”